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Context: The surgical removal of insulinomas is hampered by difficulties to localize it using con-
ventional radiological procedures. Recently these tumorswere showntoexhibit a veryhighdensity
ofglucagon-likepeptide-1 receptors (GLP-1R) in vitro thatmaybeusedas specific targets for in vivo
receptor radiolabeling.
Objective: The objective of the study was to test the 111In-labeled GLP-1R agonist 111In-DOTA-
exendin-4 in localizing insulinomas using single photon emission computed tomography in com-
bination with computed tomography images.
Design: This was a prospective open-label investigation.
Setting: The study was conducted at three tertiary referral centers in Switzerland.
Patients: Patients included six consecutive patients with proven clinical and biochemical endog-
enous hyperinsulinemic hypoglycemia.
Intervention: 111In-DOTA-exendin-4was administered iv at adoseof about 90MBq (30gpeptide)
over 5 min. Whole-body planar images of the abdomenwere performed at 20 min, 4 h, 23 h, 96 h,
and up to 168 h after injection. After surgical removal of the insulinomas, GLP-1R expression was
assessed in the tumor tissue in vitro by GLP-1R autoradiography.
Main Outcome Measure: The detection rate of insulinomas was measured.
Results: In all six cases, the GLP-1R scans successfully detected the insulinomas identified using
conventional methods in four cases. By using a -probe intraoperatively, GLP-1R detection per-
mitted a successful surgical removal of the tumors in all patients, diagnosed histopathologically as
five pancreatic and one extrapancreatic insulinomas. In vitro GLP-1R autoradiography showed a
high density of GLP-1R in all tested insulinomas.
Conclusion: In vivo GLP-1R imaging is an innovative, noninvasive diagnostic approach that suc-
cessfully localizes small insulinomas pre- and intraoperatively and thatmay in the future affect the
strategy of insulinoma localization. (J Clin Endocrinol Metab 94: 4398–4405, 2009)
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The most common cause of endogenous hyperinsulinemichypoglycemia in adults is an insulinoma (1). This neo-
plasm is typically small, benign in over 90% of the cases and
usually located within the pancreas (1). The biochemical di-
agnosis of hyperinsulinemic hypoglycemia with neuroglyco-
penic symptoms is mandatory to proceed to imaging studies
aimed at tumor localization (2, 3). Conventional imaging
studies [i.e. magnetic resonance imaging (MRI), computed
tomography (CT), endoscopic ultrasound] are the corner-
stoneof localizationdiagnosisofsuspected insulinoma(4,5).
Due to the small size of the insulin-secreting tumors, these
techniques have limited sensitivity (4–6). Methods such as
angiography and intraarterial calcium stimulation and ve-
nous sampling (ASVS) have been shown to improve the sen-
sitivity but are invasive procedures with concomitant risk for
complications (6–8).
Recently new tumor imaging methods based on peptide
receptor targeting have been successfully introduced (9). For
instance, based on the marked overexpression of somatosta-
tin receptors (sst) in neuroendocrine tumors, somatostatin
receptor targeting has been introduced as in vivo diagnostic
and therapeutic procedure in many of those neuroendocrine
tumors (10, 11). Unfortunately, somatostatin receptors, in
particular sst2, are insufficiently expressed in many insulino-
mas (12), explaining the low rate of detection with soma-
tostatin receptor scintigraphy (OctreoScan, Mallinckrodt,
Petten, The Netherlands) (10). However, another peptide
receptor, glucagon-like peptide-1 (GLP-1) receptor (GLP-
1R), has recently been brought up in relation with insulino-
mas (12).GLP-1Risapeptidehormonereceptorandamember
of the glucagon receptor family (13, 14). GLP-1 or its analog,
exenatide (Byetta,Lilly, Indianapolis, IN), isknowntoenhance
insulin secretion in the -cell and has been introduced in the
therapy of type 2 diabetes (15, 16). Remarkably GLP-1R is
expressedinveryhighdensityinalmostall insulinomas(12)and
may therefore be regarded as an interesting potential target.
Treatment strategy of insulinoma relies on surgical
removal of the tumor if possible by a simple enucleation
of the tumor. The precise preoperative but also the exact
intraoperative localization of the insulinoma is critical
to minimize the surgical intervention (5). GLP-1 like
radioligands retaining high binding affinity to GLP-1R
were recently developed including the specific ligand
[Lys40(Ahx-DOTA)NH2]exendin-4 labeled with the ra-
dioisotope indium-111 (111In-DOTA-exendin-4). Data
in rodents (17) and preliminary data in humans (18)
indicate that GLP-1 imaging using 111In-DOTA-ex-
endin-4 is capable to localize insulinoma in vivo. This
report summarizes the clinical characteristics, imaging
studies and invasive procedures of six consecutive pa-
tients with insulinoma in whom GLP-1R imaging has
been performed.
Patients and Methods
Study patients and design
In this prospective pilot study, six consecutive patients (four
females, two males) were recruited at three tertiary referral cen-
ters in Switzerland. Only patients with biochemically proven
endogenous hyperinsulinemic hypoglycemia with neuroglyco-
penic symptoms, inadequately high serum insulin and C-peptide
concentrations, and a negative screening for sulfonylurea were
included in this trial (Table 1). In addition to the conventional
preoperative localization methods, which were performed at the
respective centers, all patients underwent GLP-1R scintigraphy
maximally 14 d before elective surgery. Tumor tissue samples
obtained during surgery were used for histopathological diag-
nosis and for GLP-1R and somatostatin receptor quantification.
The study was approved by the local ethical committee
(Ethikkommission beider Basel), and written consent was obtained
in accordance with provisions of the Declaration of Helsinki.
Synthesis and radiolabeling of DOTA-exendin-4
Lys40(Ahx-DOTA)NH2 exendin-4 (DOTA-exendin-4), a
modification of exendin-4 (exenatide) was GMP custom synthe-
sized by AnaSpec, Inc. (San Jose, CA). DOTA was thereby cou-
pled via the Lys side chain of the C-terminally extended ex-
endin-4 using Ahx as the spacer between DOTA and the peptide
(19). The peptide conjugate was characterized by matrix assisted
laser desorption ionization-mass spectrometry measurements
that were done on a Voyager sSTR equipped with a Nd:YAG
laser (355 nm) (Applied BioSystems, Framingham, MA).
An aliquot of 50 ml (50 g) DOTA-exendin-4 was dissolved
in 800 ml ammonium acetate buffer [0.2 M (pH 5.0)], incubated
with 190 MBq high specific 111InCl3 (Mallinckrodt, Petten, The
Netherlands) at 95C for 5 min in the microwave oven (Biotage
Initiator, Uppsala, Sweden) and then subjected to quality control
by analytic HPLC (17).
GLP-1R imaging
Total-body planar images and single photon emission com-
puted tomography (SPECT) in combination with CT scans of the
abdomen were performed at 20 min, 4 h, and 23 h after iv in-
jection of 30 g (82–97 MBq) 111In DOTA-exendin-4. Blood
samples were taken at 1, 5, 15, 40, 60, 120, 180, and 240 min
after injection to measure blood glucose levels and blood clear-
ance of 111In-DOTA-exendin-4.
In patients 2–6, one additional total-body and SPECT/CT scan
wascarriedoutata late timepointbetween3and7dafter injection.
Imaging was performed using a dedicated Symbia T2 hybrid
SPECT/CTunit (SiemensHealthcare,Munich,Germany)equipped
with a medium-energy, parallel-hole collimator (window setting
172 and 247 keV; width 15%; 2 180° rotation; 64 projections;
128 128 matrix; 20 sec acquisition time per projection).
Low-dose CT imaging (130 kVp, 40 mAs) was carried out to
correct for attenuation effects and to provide better anatomical
localization of SPECT findings. Static total-body scans were used
to calculate the effective half-life of 111In-DOTA-exendin-4 in
the tumor and kidneys.
Finally, all patients underwent  probe guided surgery.
Conventional imaging and functional testing
MRI scans were performed in all patients using a three-pha-
sic, breath-held T1 gadolinium-enhanced protocol. Four pa-
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tients (patients 1, 2, 5, 6) had additional dual-phase, thin-section
multidetector CT scans. Endoscopic ultrasound was performed
in all patients under mild analgesia as previously described (20).
A selective ASVS was carried out in patients 2, 4, and 5 at the
University Hospital of Zurich according to the local protocol
that is described in details elsewhere (7). In patient 2, 111In-
pentetreotide total body scans were carried out 4 and 24 h after
injection of 190 MBq 111In-pentetreotide (OctreoScan).
Conventional imaging and GLP-1R scans were performed
within 2 months.
Image reporting
All conventional scans were reported independently by ex-
perienced dedicated radiologists. Two nuclear medicine physi-
cians visually assessed GLP-1R scans. Radiologists and nuclear
medicine physicians were blinded to other imaging results but
were aware of the patients’ clinical history.
In vitro analysis of the insulinoma
GLP-1R expression was evaluated in vitro by GLP-1R auto-
radiography as previously reported using 125I-GLP-1 (7–
36)amide (74 Bq/mmol; Anawa, Wangen, Switzerland) as ra-
dioligand in sections of patients’ tumor samples (21). The in vitro
autoradiography of somatostatin receptor sst1-sst5 expression
was performed in consecutive sections of the same tumor as
previously described (22).
Role of the funding source
The sponsor of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of this
manuscript. The corresponding author had full access to all the
data in this study and had final responsibility for the decision to
submit for publication.
Results
Clinical characteristics and biochemical
investigations of the patients
The clinical characteristics and biochemical investiga-
tions are summarized in Table 1. Six patients volunteered
for this study (four females, two males; age range 31–72
yr). All presented with neuroglycopenic symptoms rang-
ing from confusion, unconsciousness, up to seizures. In
three patients, neuroglycopenic symptoms lead to inves-
tigation in an accident and emergency department with
documentation of hypoglycemia. The history of the pa-
tients revealed symptoms suggestive for hypoglycemia for
4–36 months prior to the diagnosis.
Inall sixpatients, a fasting testwasperformed.Symptoms
of neuroglycopenia in association with low plasma glucose
levels (glucose range 1.3–2.1 mmol/liter) and increased in-
sulin (5.1–38.6 mU/liter) and C-peptide (range 0.8–1.7
nmol/liter) levels occurred in all patients after 7–27 h of
fasting.
Preoperative localization
The preoperative work-up is summarized in Table 2.
CT imaging was performed in four patients showing a
lesion only in one patient (patient 5). MRI was carried
out in all six patients, revealing a lesion in one patient
(patient 5). It has to be mentioned that in patient 2
(patient with an ectopic insulinoma), the tumor was
diagnosed only retrospectively in the MRI after visual-
ization of a suspicious lesion by GLP-1R imaging. En-
doscopic ultrasound was performed in all patients
TABLE 1. Clinical characteristics and biochemical evaluation of six patients with insulinoma
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Clinical characteristics
Age (yr) 31 64 49 55 44 72
Gender F M F F F M
Presenting symptom Unconsciousness,
A and E,
hypoglycemia
Confusion,
hypoglycemia
during night,
seizures?
Confusion at
night with
seizures
Confusion at
night
Confusion in
the
morning,
seizures?
Confusion, A
and E,
hypoglycemia
Duration of symptoms
(months)
4 6 6 36 24 NA
Clinical and biochemical
evaluation at the
end of the fasting
test
Duration of fasting (h) 19 20 7 11 27 13
Leading symptom Adrenergic
symptoms,
confusion
Confusion Seizures, A
and E
Confusion Somnolence Confusion
Glucose (mmol/liter) 1.6 2.1 1.9 1.3 1.5 1.9
C-peptide (nmol/liter) 1.4 1.7 0.8 0.8 0.8 1.0
Insulin (mU/liter) 5.9 38.6 11 5.1 14.8 13
F, female; M, male; A and E, Accident and Emergency Department; NA, not available.
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showing a lesion in four of six patients. ASVS was per-
formed in three patients, suggesting an insulinoma in
the vascular territory of the anterior mesenteric artery
(patient 2), gastroduodenal artery (patient 4), and the
dorsal pancreatic artery (patient 5).
GLP-1R scintigraphy (Table 2 and Figs. 1–3)
The labeling yield of 111In-DOTA-exendin-4 was
greater than 98% at a specific activity of 20 GBq/mol and
a radiochemical purity of about 90%. The blood glucose
levels after the 111In-DOTA-exendin-4 injection are sum-
TABLE 2. Preoperative and intraoperative localization and therapy of the six patients with insulinoma
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Preoperative localization
CT   NA NA  
MRI  a    
Endoscopic sonography      
ASVS NA A. mes. sup. NA A. gastroduod. A. pancr.
dors.
NA
111In-DOTA-exendin-4
SPECT/CT
     
Intraoperative localization
Ultrasound  b    
 -Probe-guided localization      
Surgical procedure Whipple Enucleation
ectopic
lesion,
Whipple
Enucleation Enucleation Enucleation Enucleation
Tumor characteristics
Histopathology Insulinoma Insulinoma Insulinoma Insulinoma Insulinoma Insulinoma
Dimension (mm) 12 13 17 11 18 9
Localization Body tail
transition
Ectopic,
mesentery
Head of
pancreas
Head of
pancreas
Body tail
transition
Tail
Receptor profile
GLP-1R density (dpm/mg tissue;
mean  SEM, n 3)
5012  495 2605  340 10,000 10,000 4891  498 NAc
sst expression 0 0 d 0 d NAc
A. mes. sup., A. gastroduod., A. pancreatica dors., Significant rise in insulin levels after injection of calcium into the arteria mesenterica superior,
arteria gastroduodenalis, arteria pancreatica dorsalis, respectively; sst, somatostatin receptor; NA, not available.
a Extrapancreatic lesion was retrospectively diagnosed after localization with 111In-DOTA-exendin-4 SPECT/CT; b lesion discovered intraoperatively
on the basis of knowledge of the findings of the 111In-DOTA-exendin-4 SPECT/CT; c not enough tissue available for receptor determination;
d subtype profile reveals low levels of sst1 and sst3.
FIG. 1. 111In-DOTA-exendin-4 whole-body planar images (A–C) and 111In-DOTA-exendin-4 SPECT/CT images (D and E) from patient 3. Whole-
body scans were carried out 20 min (A), 4 h (B), and 3 d (C) after injection, whereas SPECT/CT scans were performed 4 h (D) and 3 d (E) after
injection of 97 MBq 111In-DOTA-exendin-4. Four hours after injection, there is already focal 111In-DOTA-exendin-4 uptake visible in the head of
pancreas (arrow) on whole-body (B) and SPECT/CT (D) scans. The tumor to pancreas uptake ratio was 1.9 at 4 h after injection (D) and 3.2 at 3 d
after injection of the radioligand. The longest residence times of 111In-DOTA-exendin-4 were observed in the tumor (arrow) and kidneys (C).
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marized in Table 3. The nadir of blood glucose levels oc-
curred 40 min after the injection. The decrease in blood
glucose levels was between 0.3 and 2.4 mmol/liter. An
exogenous glucose infusion (5%) for maximum 120 min
was necessary in three patients. The quantity of infused
glucose varied from 10 g up to maximum 22.5 g. By reg-
ularly monitoring glucose levels after injection, no severe
hypoglycemic episode occurred. One patient experienced
a short episode of vomiting; otherwise, no further side
effects were observed.
Blood sampling revealed a biexponential blood clearance
of 111In-DOTA-exendin-4: t1⁄2 26 4 min and t1⁄2 85
5 min; approximately 70% of the administered dose was
cleared in the alpha phase. The clearance
occurred exclusively via the kidneys. The
longest residence times of 111In-DOTA-
exendin-4 were observed in the tumor
and kidneys (Fig. 1C). The effective half-
lifeof111In-DOTA-exendin-4was longer
in the tumor (38–64 h) than the kidneys
(31.2–31.9 h).
Patients 1, 2, 3, and 5 showed intense
111In-DOTA-exendin-4 uptake in the
tumor just 4 h after injection (see for
example patient 3 in Fig. 1, B and D).
Patient 3 also demonstrated intense up-
take at late scanning (see Fig. 1E),
whereas patients 4 and 6 showed de-
marcation between tumor and kidney
only at late scans 3–7 d after injection
(i.e. see patient 6 in Fig. 2, A–C). Tumor
to background ratio was high (3) with
the exception of the kidneys, which fea-
tured a high uptake. In patients 2 and 6,
a small area of increased activity was
observed in the region of the proximal
duodenum (i.e. see patient 6 in Fig. 2D).
Importantly, GLP-1 scintigraphy
correctly localized the insulinoma in all
six patients (Table 2 and Figs. 1–3). In
patients 1, 3, 5, and 6, the GLP-1R im-
aging was found to overlap with endoscopic ultrasound,
and in patient 4, a GLP-1 scan confirmed the lesion local-
ized by ASVS. In patient 2 the conventional imaging did
not initially show a suspicious lesion. Although ASVS cor-
rectly suggested an insulinoma in the vascular territory of
the anterior mesenteric artery in this patient, the ectopic
origin of this insulinoma would not have been detected
without GLP-1R imaging.
Intraoperative localization and surgical procedure
In all patients intraoperative palpation and ultrasound
was performed that confirmed the findings of the preop-
FIG. 2. 111In-DOTA-exendin-4 SPECT/CT images from patient 6 at 4 h (A), 23 h (B), and 6 d
(C and D) after injection of 88 MBq 111In-DOTA-exendin-4. A demarcation between tumor in
the tail of pancreas (large arrow) and left kidney was possible only at late scans 3 d after
injection of the radioligand (A–C). The tumor to kidney uptake radio improved from 0.02 at
23 h (B) to 0.10 at 3 d after injection (C). Additional focal 111In-DOTA-exendin-4 uptake was
visible in the region of the proximal duodenum (short arrow in D). This finding may be related
to the fact that the Brunner’s gland of the duodenum expresses GLP-1R in high density. The
corregistrated CT scan was important here for the localization and interpretation of this
lesion.
TABLE 3. Blood glucose levels before and after injection of 30 g (82–97 MBq) 111In-DOTA-exendin-4
Patient 1 Patient 2 Patient 3 Patient 4a Patient 5b Patient 6a
Baseline blood glucose level
(mmol/liter)
4.2 6.1 4.7 3.8 3.6 4.1
Nadir of blood glucose level
(mmol/liter)c
3.1 4.7 4.3 2.2 1.7
Blood glucose level 3 h after
injection (mmol/liter)
7.3 6.0 5.5 5.2 5.2 4.9
a Patients 4 and 6 received 350 ml (patient 4) and 450 ml (patient 6) glucose (5%) by continuous iv injection 40–160 min after injection of the
radiopeptide; b patient 5 received a total of 200 ml 5% glucose starting just before the injection of 111In-DOTA-exendin-4, and because this
patient did not show a decrease in blood glucose levels within 60 min, the infusion was stopped; c in patients 1, 2, 3, 4, and 6, the lowest blood
glucose level was measured 40 min after injection of 111In-DOTA-exendin-4.
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erative GLP-1R scans. In patient 2, however, it was ex-
tremely difficult to detect the lesion by ultrasound. Im-
portantly, in all patients the tumor was correctly localized
in situ with a -probe up to 14 d after injection of 111In-
DOTA-exendin-4. The intraoperative findings allowed
proceeding to an enucleation of the tumor in four of six
patients. In patient 1 a Whipple procedure was performed
due to the anatomical site of the lesion. In patient 2 ma-
lignant insulinoma could not be excluded by the time of
surgery, and the ASVS suggested a lesion within the head
of pancreas. However, histological work-up of the whole
surgical preparation of patient 2, including head of the
pancreas and duodenum, did not reveal an additional neu-
roendocrine tumor, thereby confirming an ectopic origin
of the insulinoma in the mesentery between duodenum
and superior mesenteric artery.
Histology and autoradiography (Fig. 4)
In all six patients, the diagnosis of benign well-differ-
entiated insulin-producing tumor was confirmed at his-
tology (Fig. 4A). The dimension of the tumors ranged from
9 to 18 mm. Receptor autoradiography of the resected
tissues samples showed a very high GLP-1R density in all
tested cases (Table 2). This strongly indicated that the hot
spots detected by in vivo imaging at the tumor site were
related to GLP-1R. Figure 4 (B–D) illustrates the GLP-1R
expression seen by receptor autoradiography in the tumor
of patient 5. Furthermore, two insulinomas expressed in
vitro low levels of somatostatin receptors: sst1 receptors
(patient 3) and sst1 and sst3 receptors (patient 5) were
detected, whereas the other subtypes, including sst2, were
absent, indicating that OctreoScan would have been neg-
ative in this series of patients (Table 2).
Discussion
This is the first report that provides the proof of concept
that 111In-DOTA-exendin-4 is a sensitive tool in preop-
eratively localizing small intra- and extrapancreatic insu-
linomas in humans. Furthermore, the precise intraopera-
tive localization of insulinoma using a -probe is highly
beneficial for the surgical strategy.
FIG. 4. Hormone and receptor determinations in vitro in the
insulinoma of patient 5. A, Immunohistochemistry for insulin showing
strongly labeled tumor cells. Bar, 0.01 mm. B–D, GLP-1R
autoradiography. B, Hematoxylin-eosin-stained tumor tissue. Bar, 1
mm. C, Autoradiogram showing total binding of 125I-GLP-1 (7–36)
amide. Whole tumor is strongly positive. D, Autoradiogram showing
nonspecific binding of 125I-GLP-1 (7–36) amide in the presence of 100
nM GLP-1 (7–36) amide.
FIG. 3. Coronal SPECT/CT image from patient 4 (A) and transaxial
SPECT/CT image from patient 5 (B) at 3 d after injection of about
90 MBq 111In-DOTA-exendin-4. In patient 4 the insulinoma is
located in the head of pancreas (arrow), whereas in patient 5 the
insulinoma is visible in the body-tail transition of the pancreas
(arrow). The tumor to pancreas uptake ratio was greater than 3 in
both patients.
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Remarkably GLP-1R scintigraphy correctly detected
the insulinoma in all six consecutive patients. This novel
technique is more sensitive than conventional CT or MRI
that detected a suspicious lesion in only one patient,
whereas endosonography suggested a lesion in four pa-
tients. These conventional imaging data are consistent
with previous reports indicating a detection rate of about
60% for MRI or CT scan (23), whereas for endosonog-
raphy sensitivities up to 80–90% are reported (5, 20).
ASVS was performed in three of six patients. This proce-
dure reliably identified the area of localization of the in-
sulinoma in all three patients, in keeping with previous
results of the same institution (7). However, the results of
ASVS always indicate only the region of the pancreas in
which the insulinoma should be located and not the tumor
itself. This region is related to the vascular territory of the
corresponding artery (7). In patient 2, the results of the
ASVS correctly suggested an insulinoma within the region
supplied by the anterior mesentery artery, but because this
patient had an ectopic insulinoma within the mesentery,
the results of the ASVS without GLP-1R imaging would
have been misleading for the surgical strategy. Finally,
GLP-1R scintigraphy may be superior to the recently re-
ported 18F-DOPA-PET imaging (24) because tumor to
pancreas uptake ratios are higher for 111In-DOTA-ex-
endin-4 SPECT than for 18F-DOPA PET (3.3 vs. 1.4).
One strength of the current study is the concomitant
determination of GLP-1R in vitro and in vivo using 111In-
DOTA-exendin-4. The in vitro data clearly indicate that
the in vivo hot spots correspond to the GLP-1R of the
insulinomas. GLP-1R density as assessed in the current
study by autoradiography is highly consistent with previ-
ous results (12). In general, for in vivo tumor targeting,
receptor density is critical for sensitivity of the technique
(25). This explains the high sensitivity of 111In-DOTA-
exendin-4 as reported in the current study.
Within a time frame of 2–14 d after injection of 111In-
DOTA-exendin-4, intraoperative use of a -probe was
highly beneficial for the in situ localization in all patients
(Fig. 3 and Table 2). It influenced the surgical procedure
in four of six patients that permitted a successful enucle-
ation of the insulinoma and detected the ectopic insuli-
noma. In contrast, the traditional gold standard, i.e. in-
traoperative ultrasound with manual palpation, yields a
sensitivity of only about 80% and is not helpful in ectopic
insulinoma (1).
Fortunately, GLP-1R scans showed a high tumor to
background ratio in all patients. Background uptake over
the whole body was low with the exceptions of the kid-
neys, which were strongly labeled owing to renal excretion
of the radioligand. In patients 4 and 6, demarcation be-
tween tumors with a maximal diameter of 9–11 mm and
kidneys was possible only after late scans, indicating an
improved tumor to kidney ratio with time. In fact, the
effective half-life of 111In-DOTA-exendin-4 was longer in
the tumor (38–64 h) than the kidneys (31.2–31.8 h). This
suggests that patients with negative early scans should
have additional imaging 3–7 d after the injection. Further-
more, in two patients (patients 2 and 6), there was focal
111In-DOTA-exendin-4 uptake in the proximal duode-
num (Fig. 2D). This finding may be related to the fact that
the Brunner’s gland of the duodenum expresses GLP-1R in
high density (21).
In conclusion, these data, although based on a limited
number of consecutively enrolled patients, strongly sug-
gest that GLP-1R scintigraphy offers a new approach that
permits the successful localization of small insulinomas
pre- and intraoperatively. Because virtually all insulino-
mas express GLP-1Rs, it is likely that this approach will
affect the algorithm of pre- and intraoperative localization
of suspected insulinoma. It is expected that the success rate
of this new technique is very high.
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